Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGM NASDAQ:FENC NASDAQ:PHAT NASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$9.52+0.3%$8.76$6.22▼$17.17$922.64M1.3324,512 shs1,494 shsFENCAdherex Technologies$8.72+0.7%$8.83$3.96▼$9.92$241.71M0.6477,269 shs79,008 shsPHATPhathom Pharmaceuticals$14.00-0.1%$11.85$2.21▼$19.50$993.92M0.431.40 million shs674,041 shsRAPPRapport Therapeutics$26.78+1.3%$22.52$6.43▼$42.27$964.64M1.68520,810 shs373,263 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+0.32%-0.83%-4.13%-3.35%+23.00%FENCAdherex Technologies+0.69%+5.44%+0.58%-0.11%+87.12%PHATPhathom Pharmaceuticals-0.07%+12.00%+24.89%+63.36%-9.79%RAPPRapport Therapeutics+1.32%+7.64%+1.59%+72.77%+8.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$9.52+0.3%$8.76$6.22▼$17.17$922.64M1.3324,512 shs1,494 shsFENCAdherex Technologies$8.72+0.7%$8.83$3.96▼$9.92$241.71M0.6477,269 shs79,008 shsPHATPhathom Pharmaceuticals$14.00-0.1%$11.85$2.21▼$19.50$993.92M0.431.40 million shs674,041 shsRAPPRapport Therapeutics$26.78+1.3%$22.52$6.43▼$42.27$964.64M1.68520,810 shs373,263 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+0.32%-0.83%-4.13%-3.35%+23.00%FENCAdherex Technologies+0.69%+5.44%+0.58%-0.11%+87.12%PHATPhathom Pharmaceuticals-0.07%+12.00%+24.89%+63.36%-9.79%RAPPRapport Therapeutics+1.32%+7.64%+1.59%+72.77%+8.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMBGM Group 1.00SellN/AN/AFENCAdherex Technologies 2.50Moderate Buy$13.3352.91% UpsidePHATPhathom Pharmaceuticals 2.71Moderate Buy$17.5025.00% UpsideRAPPRapport Therapeutics 2.80Moderate Buy$35.3331.94% UpsideCurrent Analyst Ratings BreakdownLatest FENC, PHAT, RAPP, and BGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025FENCAdherex TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/8/2025BGMBGM GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025FENCAdherex TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PHATPhathom PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RAPPRapport TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BGMBGM GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025FENCAdherex TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PHATPhathom PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RAPPRapport TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/16/2025RAPPRapport TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.009/12/2025RAPPRapport TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMBGM Group$25.10M36.87N/AN/A$7.34 per share1.30FENCAdherex Technologies$33.30M7.31$0.03 per share268.15($0.21) per share-41.52PHATPhathom Pharmaceuticals$55.25M17.98N/AN/A($3.71) per share-3.77RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AFENCAdherex Technologies-$440K-$0.42N/AN/AN/A-35.05%N/A-23.92%11/6/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$4.73N/AN/AN/A-289.51%N/A-90.40%11/6/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$2.50N/AN/AN/AN/A-29.99%-28.64%11/6/2025 (Estimated)Latest FENC, PHAT, RAPP, and BGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025FENCAdherex Technologies$0.16N/AN/AN/A$13.43 millionN/A11/6/2025Q3 2025PHATPhathom Pharmaceuticals-$0.30N/AN/AN/A$47.03 millionN/A11/6/2025Q3 2025RAPPRapport Therapeutics-$0.77N/AN/AN/AN/AN/A8/14/2025Q2 2025FENCAdherex Technologies-$0.06-$0.11-$0.05-$0.11$9.52 million$9.76 million8/7/2025Q2 2025RAPPRapport Therapeutics-$0.87-$0.75+$0.12-$0.75N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGMBGM GroupN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMBGM GroupN/A1.821.45FENCAdherex TechnologiesN/A4.854.59PHATPhathom PharmaceuticalsN/A2.382.35RAPPRapport TherapeuticsN/A22.7522.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMBGM GroupN/AFENCAdherex Technologies55.51%PHATPhathom Pharmaceuticals99.01%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipBGMBGM Group58.66%FENCAdherex Technologies10.98%PHATPhathom Pharmaceuticals24.10%RAPPRapport Therapeutics13.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMBGM Group29897.22 million40.19 millionN/AFENCAdherex Technologies1027.91 million24.85 millionOptionablePHATPhathom Pharmaceuticals11070.94 million53.85 millionOptionableRAPPRapport TherapeuticsN/A36.50 million31.55 millionN/AFENC, PHAT, RAPP, and BGM HeadlinesRecent News About These CompaniesTD Asset Management Inc Has $2.24 Million Stock Position in Rapport Therapeutics, Inc. $RAPP2 hours ago | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 5,833 SharesOctober 17, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Insider David Bredt Sells 8,500 SharesOctober 17, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Insider Sells $219,215.00 in StockOctober 17, 2025 | insidertrades.comRapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Moderate Buy" by BrokeragesOctober 16, 2025 | americanbankingnews.comRapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by BrokeragesOctober 11, 2025 | marketbeat.comWeiss Ratings Reaffirms Sell (D-) Rating for Rapport Therapeutics (NASDAQ:RAPP)October 10, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 2.3% - What's Next?October 9, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 2.3% - Time to Buy?October 9, 2025 | marketbeat.comRapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body AnimationOctober 7, 2025 | businesswire.comWhy Rapport Therapeutics (RAPP) Is Up 6.3% After Positive Phase 2a Epilepsy Drug Results and Analyst OptimismOctober 2, 2025 | finance.yahoo.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 7.3% - Here's What HappenedOctober 2, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - Time to Sell?October 1, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading 4.3% Higher - Should You Buy?September 30, 2025 | marketbeat.comJMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study SuccessSeptember 30, 2025 | insidermonkey.comJMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study SuccessSeptember 30, 2025 | finance.yahoo.comRapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit TranscriptSeptember 17, 2025 | seekingalpha.comTruist Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Buy RecommendationSeptember 17, 2025 | msn.comRapport Therapeutics initiated with a Buy at TruistSeptember 16, 2025 | msn.comRapport assigned a new Buy at Truist on lead programSeptember 16, 2025 | msn.comRapport Therapeutics director buys $1.03M in common stockSeptember 15, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFENC, PHAT, RAPP, and BGM Company DescriptionsBGM Group NASDAQ:BGM$9.52 +0.03 (+0.32%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$9.41 -0.11 (-1.16%) As of 10/21/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Adherex Technologies NASDAQ:FENC$8.72 +0.06 (+0.69%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$8.72 0.00 (0.00%) As of 10/21/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Phathom Pharmaceuticals NASDAQ:PHAT$14.00 -0.01 (-0.07%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$14.00 +0.01 (+0.04%) As of 10/21/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Rapport Therapeutics NASDAQ:RAPP$26.78 +0.35 (+1.32%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$23.03 -3.75 (-13.99%) As of 10/21/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
